Mvasi, the first oncology therapeutic biosimilar approved by the FDA, is approved for the treatment of five types of cancer: in combination with chemotherapy for
metastatic colorectal cancer, or mCRC; in combination with chemotherapy for non-squamous non-small cell lung cancer, or NSCLC; recurrent glioblastoma; in combination with interferon-alfa for
metastatic renal cell carcinoma; and in combination with chemotherapy for persistent, recurrent, or
metastatic cervical cancer.
- Two original cohorts are being expanded and four new cohorts are being added to the protocol for COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with locally advanced or
metastatic solid tumors, US-based Exelixis, Inc.
Pfizer stated that the product has been approved to treat five types of cancer, including
metastatic colorectal cancer; unresectable, locally advanced, recurrent or
metastatic non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma;
metastatic renal cell carcinoma (RCC) and persistent, recurrent or
metastatic cervical cancer.
For
metastatic castration-resistant prostate cancer (CRPC), the results of the TAX 327 (6) and SWOG-9916 (7) trials using docetaxel showed overall survival benefit relative to mitoxantrone.
This report analyzes the current and future scenario of the global
Metastatic Bone Disease Market.
Summary: This report analyzes the current and future scenario of the global
Metastatic Bone Disease Market.
ISLAMABAD -- A new approach to cancer therapy suggests that doctors may be able to keep cancer in check by placing
metastatic cells in a state of dormancy, thus blocking them from giving rise to new tumors.
- First presentation of LENVIMA and KEYTRUDA combination data in patients with
metastatic non-small cell lung cancer,
metastatic melanoma and
metastatic urothelial carcinoma from Study 111/KEYNOTE-146
Metastatic neoplasms affecting the pancreas account for <2% of all malignancies in the pancreas and RCC is the most common malignancy among them.
It the past, the average survival rates for a woman diagnosed with
metastatic breast cancer used to be two to three years.
Cancer that spreads to distant parts of the body is known as
metastatic cancer and is often referred to as "stage IV cancer." According to the National Cancer Institute, when observed under a microscope,
metastatic cancer cells feature traits like that of the primary cancer and do not mimic the cells in the part of the body where the cancer is found.